Plain-English translation of NCT06585514 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing anti-CD19 chimeric antigen receptor T cells — a type of cell therapy that uses your own immune cells to help fight lupus. Researchers want to learn whether this treatment is safe and whether it works for people with severe lupus or lupus-related kidney disease that hasn't responded to other medications.
Many people with lupus don't get better even after trying multiple standard treatments, and they need new options. This trial exists to see if this new cell therapy approach can help people whose lupus has been difficult to control.
You likely qualify if…
You likely don't qualify if…
You would first receive treatment to prepare your body (called lymphodepletion), then receive an infusion of the new immune cells as a single dose. The trial will monitor you closely for at least 28 days after the infusion to watch for side effects and see how your lupus responds. You'll need to visit the research center for blood tests, exams, and follow-up visits throughout the study.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
China
Phase
Safety & dosing / Early efficacy
Sponsor
Beijing GoBroad Hospital
Enrollment target
~18 participants
Started
October 2024
Primary completion
September 2026
Age range
3 Years – 65 Years
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tengyu Wang
Beijing GoBroad Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.